IDEXX Laboratories Reaffirms Long-Term Growth Targets Amid Diagnostic Innovation
During the Morgan Stanley Global Healthcare Conference, IDEXX Laboratories reaffirmed its long-term growth targets of more than 10% organic revenue and over 15% EPS growth. The company highlighted momentum in recurring revenues from reference laboratories and point-of-care diagnostics, despite an expected decline in veterinary visits later this year. CEO Mike Erickson noted strong second-quarter performance driven by innovation across diagnostic platforms like the inVue Dx cytology system and Catalyst tests. IDEXX also emphasized a growing global pet population and increased medicalization of pets as tailwinds for its business. CFO Andrew Emerson acknowledged an anticipated 1.5% decline in veterinary visits during the second half but noted better-than-expected results so far this year, particularly with non-discretionary care remaining resilient. The company remains focused on expanding diagnostic offerings and commercial teams while maintaining a full-year operating margin target above 32%. Erickson cited an underpenetrated $45 billion global diagnostics market as key to long-term growth.
Tickers: $IDXX